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Abstract
Background: Plasmalemmal vesicle associated protein-1 (PV-1) is selectively expressed in human
brain microvascular endothelial cells derived from clinical specimens of primary and secondary
malignant brain tumors, cerebral ischemia, and other central nervous system (CNS) diseases
associated with blood-brain barrier breakdown. In this study, we characterize the murine CNS
expression pattern of PV-1 to determine whether localized PV-1 induction is conserved across
species and disease state.
Results: We demonstrate that PV-1 is selectively upregulated in mouse blood vessels recruited by
brain tumor xenografts at the RNA and protein levels, but is not detected in non-neoplastic brain.
Additionally, PV-1 is induced in a mouse model of acute ischemia. Expression is confined to the
cerebovasculature within the region of infarct and is temporally regulated.
Conclusion: Our results confirm that PV-1 is preferentially induced in the endothelium of mouse
brain tumors and acute ischemic brain tissue and corresponds to blood-brain barrier disruption in
a fashion analogous to human patients. Characterization of PV-1 expression in mouse brain is the
first step towards development of rodent models for testing anti-edema and anti-angiogenesis
therapeutic strategies based on this molecule.
Background
Vasogenic cerebral edema causes significant morbidity
and mortality in patients with malignant brain tumors.
Cytokines secreted by the growing tumor such as VEGF,
PDGF, and SF/HGF increase the permeability of the
blood-brain barrier (BBB) causing extracellular fluid accu-
mulation. The increase in extracellular fluid, in turn, raises
intracranial pressure leading eventually to brain ischemia,
herniation, and death. The situation repeats itself in the
setting of cerebral infarction where the initial intracellular
swelling associated with cytotoxic edema is later com-
pounded by cytokine release and vasogenic edema. Clini-
cal attempts to block these cascades have focused on
inhibiting signal transduction by the circulating
cytokines, including monoclonal antibodies targeted to
VEGF and selective receptor tyrosine kinase inhibitors. An
equally attractive approach may be to identify selective
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targets on the endothelial cells themselves, which are
associated with BBB alterations.
In our previous studies of blood-brain barrier breakdown
and endothelial changes in malignant glioma, we have
described several microvascular endothelial genes associ-
ated with BBB alterations. Using this approach, PV-1 was
identified as a Glioma Endothelial Marker (GEM), a
microvascular endothelial marker that is upregulated by
glioma signaling [1-3]. PV-1 encodes a transmembrane
protein that is associated with the caveolae of fenestrated
microvascular endothelial cells. It is normally expressed
in the lung, liver, kidney, and immature brain of rodents
[4]. However, intracerebral expression of PV-1 is silenced
during normal differentiation of the blood-brain barrier,
where transendothelial transport is inhibited [5]. Prelimi-
nary work has demonstrated that PV-1 expression is not
only upregulated in malignant brain tumors, but it is also
induced in cases of acute ischemia/stroke [6]. Downregu-
lation of PV-1 via PV-1 targeted siRNA, decreases endothe-
lial tubule formation normally induced by Matrigel [6].
Therefore, we suggested that PV-1 upregulation may indi-
cate a general state of blood-brain barrier disruption and
endothelial activation, such as would be associated with
malignancy, ischemia, or trauma.
We hypothesized that the expression of mouse PV-1
would parallel the expression of human PV-1 described
previously. In the current study, we demonstrate upregu-
lation of PV-1 protein expression in the mouse cerebrov-
asculature, using human glioblastoma (GBM) cell lines
grown as intracranial xenografts. We also describe induc-
tion of PV-1 in a mouse model of acute ischemia, further
expanding the role of PV-1 in states of blood-brain barrier
disruption. These data confirm PV-1 expression as a
marker of BBB dysfunction and should contribute to the
generation of a rodent model for the development and
preclinical testing of anti-angiogenic and anti-edema ther-
apies targeted towards PV-1.
Results and Discussion
Expression of PV-1
Previous studies in our laboratory have shown that PV-1
expression, normally silenced in non-neoplastic human
brain, is upregulated in highly vascularized, human
malignant brain tumors in vivo and is stimulated by VEGF
in vitro [6]. We questioned whether mouse PV-1 expres-
sion would be induced in intracranial U87:U87/VEGF
xenografts. The U87:U87/VEGF xenograft model is gener-
ated by injecting a 1:5 ratio of VEGF-overexpressing
U87MG cells to untransfected U87MG cells [7] and per-
sonal communication]. Xenografts derived using this
combination of cell lines demonstrate increased tumor
vascularity, which facilitates detection of endothelial cells
and small vessels, and better mimic the pathophysiology
of human GBM tumors. RT-PCR was performed using
murine specific PV-1  primers on mRNA isolated from
standard U87MG mouse brain xenografts as well as
U87:U87/VEGF xenografts. RT-PCR revealed that both
xenograft tumor strains upregulated the expression of PV-
1 in comparison to normal mouse brain. Flk-1 served as a
positive control endothelial marker with comparable
expression across all mouse brain samples (Figure 1A).
Quantitative RT-PCR analysis of PV-1 expression in tumor
versus normal tissues showed that while the U87MG
tumors did consistently induce PV-1 RNA, the degree of
RNA upregulation was several fold higher in the
U87:U87/VEGF tumors (Figure 1B). Interestingly, we
have had difficulty detecting PV-1 mRNA by in situ hybrid-
ization in standard, less vascular U87MG xenografts (data
not shown), although we could detect protein upregula-
tion by immunohistochemistry in the same sections, sug-
gesting that VEGF may contribute to the increased
expression of PV-1 mRNA as well as increasing tumor vas-
cularity.
PV-1 mRNA expression in intracranial glioma xenografts Figure 1
PV-1 mRNA expression in intracranial glioma xenografts. A. 
RT-PCR for PV-1 was performed on reverse-transcribed 
RNA harvested from U87MG tumors (T1) and U87:U87/
VEGF tumors grown in mice (T2, T3) and compared to PV-1 
expression levels in normal mouse brain (NL). Reactions 
were normalized using primers to the mouse endothelial 
gene, flk-1. B. Quantitative RT-PCR analysis of PV-1 expres-
sion. Reactions were normalized to flk-1. Numerical values 
for the fold increase are indicated. *Statistically significant dif-
ference between the levels of PV-1 expression in NL vs. T2 
and NL vs. T3 (p = 0.05).BMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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Localization of PV-1 expression
While PV-1 upregulation in mouse intracranial xenografts
was detectable by RT-PCR, we wanted to confirm its
induction and ensure that expression was localized to the
tumor endothelium. Our studies have previously demon-
strated that PV-1 colocalizes with endothelial control
markers such as CD31 in human glioma vasculature [2].
Recent genomic data have demonstrated that mouse
endothelial cell antigen 32 (meca-32) is identical to PV-1.
The well-characterized monoclonal antibody, meca-32,
was therefore used to detect PV-1, and the endothelial spe-
cific marker, CD31, was used as a positive control. Expres-
sion of PV-1 was strictly localized to the endothelium in
the mouse brain tumors, and was consistently expressed
throughout the tumor, from the core of the tumor to the
tumor margin (Figures 2A, B). Non-neoplastic brain
showed positive CD31 staining, but no PV-1 reactivity,
indicating that glioma cells specifically induce the expres-
sion of PV-1 in mouse brain tumor endothelium (Figure
2B). Control tissues, which were not incubated with the
primary antibodies, showed no endothelial PV-1 staining
(data not shown).
PV-1 expression in acute ischemia
Previous studies in our laboratory have shown that PV-1
expression can also be upregulated in human patients
who suffered from acute ischemia/stroke [6]. In order to
demonstrate conservation of this response across species
and to better characterize the timing of the response, we
measured expression of PV-1 in acute ischemic mouse
brains at 8 hours, 24 hours, 48 hours, and 7 days post-
ischemia. Immunohistochemistry was performed on fro-
zen brain sections to detect PV-1 and the positive control
endothelial marker, CD31. As in normal brain, there was
no PV-1 expression in the 8 hour or 24 hour post-
ischemia mouse brain samples (Figure 3A). However,
sparse PV-1 staining was present at 48 hours post
ischemia, and dramatic upregulation was detected at 7
days post-ischemia, with PV-1 present in the majority of
the vessels within the lesion. Induction of PV-1 occurred
throughout the ischemic region and was not preferentially
associated with any specific structure or domain (Figure
3B). All PV-1 staining was strictly localized to the area of
ischemic damage, and not observed in the surrounding
normal brain tissue. Mice that underwent sham surgeries
did not express intracerebral PV-1. CD31 staining was
positive for all samples (Figure 3A). Vessel quantitation
confirmed that while no PV-1 was detected at 8 hours or
24 hours after injury, the number of PV-1 positive vessels
increased to approximately 17% of CD31 expressing ves-
sels by 48 hours. By 7 days post-ischemia, upregulation of
PV-1 resulted in no statistical difference between the
number of PV-1 positive vessels and CD31 positive vessels
(Figure 4).
Conclusion
The blood-brain barrier (BBB) plays a central role in
maintaining fluid homeostasis in the brain. Microvascular
endothelial cells are the anatomic basis of the BBB, which
is comprised of both intercellular tight junctions that pre-
vent paracellular transport as well as the tightly regulated
facilitated transport systems that modulate intracellular
transport. Loss of integrity of the BBB is a hallmark of
numerous central nervous system pathologies, including
malignant brain tumors and ischemic stroke. Failure of
the BBB leads to increased fluid permeability in the cere-
bral microvasculature and extracellular fluid accumula-
tion associated with vasogenic edema. This edema, due to
leakage from abnormal tumor or ischemic blood vessels,
generates increased intracranial pressure and contributes
to neurologic deficits, secondary brain injury, herniation
and, in the worst cases, death. However, while recent stud-
ies have advanced our understanding of the molecular
mechanisms of the intact BBB, less is known about the
endothelial gene expression changes associated with BBB
breakdown.
Our previous studies of microvascular gene expression in
glioblastoma identified PV-1 as a cell surface protein spe-
cifically upregulated in the endothelium of malignant
brain tumors. In addition, we detected endothelial PV-1
re-expression in cases of acute ischemia. PV-1 was initially
described as a microvesicular transport protein in the
immature brain of rodents [4]. Induction of PV-1 expres-
sion stimulated the formation of stomatal diaphragms of
caveolae, as well as transendothelial channels for micro-
vesicular transport [8]. Inhibition of PV-1  expression
using siRNA inhibited the expression of these structures
associated with microvesicular transport [8]. While PV-1
is expressed normally in the adult lung, kidney and endo-
crine tissues of a rodent, its expression in the central nerv-
ous system is limited to the undifferentiated BBB and it is
silenced in sites of intact BBB [4]. Re-expression of PV-1
suggests that this protein may play a functional role in
BBB disruption and remodeling seen in tumors and after
ischemic insults.
The development of effective vascular targeting strategies
requires an improved understanding of the molecular
changes that drive microvascular responses, as well as
appropriate animal models in which to develop and test
therapeutic regimens. However, our understanding of the
relationship between human and rodent endothelial biol-
ogy is still evolving. For example, impressive results using
anti-angiogenic approaches in rodent trials are often not
reproducible in humans [9]. This could be due, in part, to
species-specific differences in the genes regulating
endothelial phenotypes. Since PV-1 is a transmembrane
protein, accessible via the bloodstream, it is an especially
intriguing molecule. Characterization of PV-1 expressionBMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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PV-1 protein expression in intracranial glioma xenografts Figure 2
PV-1 protein expression in intracranial glioma xenografts. A. Immunohistochemistry for PV-1 was performed on frozen brain 
sections containing U87:U87/VEGF tumors (T1, T2) or normal brain (NL); 100×. PV-1 expression was detected solely on the 
microvessels within the tumors and showed a comparable staining pattern to that of the endothelial control marker, CD31. 
PV-1 expression was not detected in normal brain as compared to CD31. B. The interface between normal brain (NL) and 
brain tumor (T) demonstrated that PV-1 expression was tightly restricted to the tumor; overview 40×, detail 100×.BMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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PV-1 protein expression after ischemic insult Figure 3
PV-1 protein expression after ischemic insult. A. Top row, PV-1; bottom row, CD31; 100×. PV-1 is not detected 8 or 24 hours 
after ischemia, unlike the endothelial control marker, CD31. PV-1 expression is detectable in a small number of vessels in the 
affected tissue 48 hours after injury. PV-1 protein is expressed in a majority of the vessels and is comparable to CD31 staining 
levels in the injured region by 7 days after injury. Sham (uninjured brain) shows no expression of PV-1. B. Overview of PV-1 
expression within the ischemic region 48 h and 7d after injury. PV-1 is induced throughout the affected brain tissue at 48 h (see 
arrows) and remains evenly distributed by 7d.BMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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in a rodent model was therefore our next step towards the
development of targeted therapy for glioma and stroke
patients.
Intracranial U87:U87/VEGF mouse xenografts were cre-
ated as a model for brain malignancy. The addition of the
VEGF-overexpressing U87 cells (U87/VEGF) at the time of
injection increased the vascular proliferation within the
xenografts [7]. This made the xenografts more similar to
human GBMs, which are highly vascularized, and facili-
tated analysis of gene expression within the tumor
endothelium. However, we noted similar results using
standard, unmodified U87MG intracranial xenografts as
well. RT-PCR and quantitative RT-PCR of the resected
mouse brains showed increased expression of PV-1 in the
mouse xenografts in comparison to non-neoplastic
mouse brains. Results were normalized to flk-1 to account
for the increased vascularity of tumor versus normal brain
tissue, thus ensuring that the increase in PV-1 expression
was not simply due to an increase in the number of
endothelial cells, but to tumor-related gene induction.
This upregulation of PV-1 in the mouse xenograft parallels
the increase in PV-1 expression seen in high grade human
brain tumor samples [1,6]. The analyzed tumors were har-
vested between 28 and 34 days after intracranial injection
of tumor cells. Attempts to investigate PV-1 expression at
earlier times resulted in tumors that were undetectable or
were small and poorly vascularized, leading to inconclu-
sive results. Although larger, more stringent time course
studies are required, this suggests that PV-1 is induced in
large, well-vascularized tumors in mice, which is similar
to the human state, where PV-1 is preferentially expressed
in high-grade, well-vascularized astrocytomas (GBMs)
than grade I/II astrocytomas [6].
Immunohistochemistry was performed to ensure protein
expression was localized to the endothelium in the mouse
xenografts (Figure 2). In addition, the endothelial expres-
sion of PV-1 was not generalized to the entire brain, but
localized to the tumor. Non-neoplastic brain did not
show any positive PV-1  staining, but did demonstrate
CD31 reactivity. Additionally, PV-1  expression was
detected using meca-32, which is a mouse-specific
endothelial antibody. This indicates that the vasculature
recruited to supply the tumor was of mouse origin and not
human material.
Since preliminary studies in our laboratory have shown
the upregulation of PV-1 in human acute ischemia sam-
ples, we next used an animal model of acute ischemia to
determine if PV-1  was upregulated in ischemic mouse
brain samples. In addition, the "on-off" nature of the
MCAO injury makes it more amenable to time course
studies than tumor models. While there was no upregula-
Vessel quantitation after ischemic insult Figure 4
Vessel quantitation after ischemic insult. Dark bars, PV-1; open bars, CD31. Five high power fields were counted per mouse 
brain. Data are expressed as mean +/- standard error of the mean. *Statistically significant difference between the number of 
PV-1 positive and CD31 positive vessel (p < 0.001, 95% CI). **No statistically significant difference between number of PV-1 
vessels and CD31 vessels (p > 0.05).BMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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tion of PV-1 at 8 hours or 24 hours post-ischemia, mini-
mal PV-1 expression was detected 48 hours after the
ischemic insult, followed by a dramatic increase in PV-1
expression 7 days after the ischemic injury. In all cases,
detection of PV-1 was confined to the area of ischemia,
and did not extend into the normal, uninjured brain. The
delay in PV-1 expression may be attributed to the time
required to synthesize the protein de novo. The observa-
tion that PV-1 is strongly expressed 7 days after injury also
suggests that this protein may be associated with revascu-
larization of the damaged tissue and the protein may be
induced in new, immature microvessels, similar to those
found in aggressive tumors [10,11].
So while PV-1  expression in the cerebrovasculature is
completely suppressed by the intact, differentiated BBB, it
is dramatically induced during states of BBB disruption
such as malignancy and ischemia in both human and
rodent brain. The progression and recurrence of malig-
nant brain tumors is associated with the expression of
pro-angiogenic growth factors, such as VEGF and SF/HGF
(reviewed in [12,13]). Tumor associated angiogenesis
results in markedly abnormal vessels [14,15]. These ves-
sels are poorly organized, irregular and tortuous. Further-
more, the new vessels tend to be leaky and hemorrhagic,
partly due to induction of VEGF, with disrupted cell-cell
junctions and loosely adherent or absent pericytes [16].
This leads to failure of the BBB integrity and contributes to
vasogenic edema in advanced brain tumors. Similarly,
hypoxia has been shown to induce expression of VEGF 48
hours to 72 hours after ischemic insult and has been
linked to induction of neoangiogenesis by 3 days post
injury [17,18]. Hypoxia-induced VEGF expression after
cerebral ischemic insult precedes edema while VEGF
antagonism can reduce the post-ischemic edema and
associated tissue damage [18,19]. We, and others, have
shown that exogenous VEGF induces the expression of
PV-1 in cultured endothelial cells [3,6]. PV-1 expression
has also been correlated with microvascular leakage in
diabetic retinopathy, indicative of a role for this protein in
disruption of the blood-occular barrier [20]. Re-expres-
sion of PV-1, a cell surface protein with a putative function
in transendothelial transport, in brain malignancy and
acute ischemia, suggests that this protein may play an
active role in BBB leakiness. The characterization of PV-1
expression in murine models could be a first step towards
development of PV-1 targeted strategies.
Methods
Cell Culture
U87MG tumor cells (ATCC, Manassas, VA) were main-
tained in Minimum Essential Medium Eagle with Earle's
Salts and L-glutamine (Invitrogen, Carlsbad, CA), supple-
mented with 10% FBS, 0.1 mM MEM non-essential amino
acids, 0.1 mM MEM sodium pyruvate, sodium bicarbo-
nate, and antibiotics. U87MG/VEGF165 cells (gift of Dr.
Shiyuan Cheng, University of Pittsburgh) were main-
tained in Dulbecco's Modified Eagle's Medium (Invitro-
gen) supplemented with 10% FBS and antibiotics.
RNA Isolation and Reverse Transcription
Tumors were dissected free from non-neoplastic tissue.
RNA was isolated from 10–30 mg of frozen, homogenized
tumor or normal brain from a control mouse using the
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA
was generated using the SuperScript First-Strand Synthesis
System (Invitrogen). Briefly, 5 μg of total RNA was com-
bined with oligo(dT)12–18 primers, heat denatured and
reverse transcribed with SuperScript II RT. An RT-minus
control was performed for each reverse transcription reac-
tion. Equivalent volumes of RT-plus and RT-minus prod-
ucts were used as templates for amplification.
PCR
Primers were synthesized by IDT (Coralville, IA). Primer
sequences were PV1(F) 5'-gccagaagttggagctagagcg-3',
PV1(R) 5'-ggagcagagtgataggaaaccg-3', FLK1(F) 5'-gccag-
ggcaaggactacg-3', FLK1(R) 5'-ggtagtgtagtcaggagcccg-3'.
Standard reaction conditions were 1× PCR buffer, 200
mM dNTPs (Invitrogen), 4% DMSO (Sigma), 1.5 mM
MgCl2, 1 μM sense primer, 1 μM antisense primer, 1.5
units Platinum Taq (Invitrogen), and 2 μl cDNA in a total
reaction volume of 25 μl. Reactions were overlaid with
mineral oil and cycled in a PTC-200 thermalcycler (MJ
Research, Waltham, MA).
Quantitative RT-PCR
qRT-PCR was carried out on triplicate samples for 40
cycles of 10s at 95°C, 30s at 60°C after an initial incuba-
tion at 95°C for 3 min in an Chromo4 thermal cycler
(Bio-Rad, Hercules, CA). Reaction conditions were 1× iQ
SYBR Green super mix (Bio-Rad), 400 nM forward and
reverse primers, and 2.0 μl cDNA in a total reaction vol-
ume of 25 μl. Amplification of flk-1 was performed for
each cDNA in triplicate for normalization of RNA content.
Primer sequences were: PV1q(F) 5'-gggtggttggaaatga-
tactgg-3', PV1q(R) 5'-cacgatgccatgctggtcac-3', FLK1q(F) 5'-
ttccgccagtgccaagg-3', FLK1q(R) 5'-gccacctccatctccagtgtc-3'.
Threshold cycle number (Ct) of amplification in each
sample was determined by Bio-Rad software. Relative
mRNA abundance was calculated as the Ct for amplifica-
tion of PV-1 minus average Ct for flk-1, expressed as a
power of 2, i.e. 2-ΔCt. Three individual PV-1 values were
averaged to obtain mean ± SD. Statistical significance was
determined using a Wilcoxon rank sum test.
Intracranial xenografts
U87MG cells were harvested with trypsin (Invitrogen) and
resuspended at a concentration of 105 cells/10 μl antibi-
otic-free DMEM. For increased vascularity, U87MG/BMC Neuroscience 2008, 9:29 http://www.biomedcentral.com/1471-2202/9/29
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VEGF165 cells and U87MG cells were harvested and resus-
pended at a 1:5 ratio for a final concentration of 105 cells/
10  μl antibiotic-free DMEM (U87:U87/VEGF tumors).
Athymic nu/nu mice (NCI, Frederick, MD) were anesthe-
tized using an intraperitoneal injection of 3 ml/kg xyla-
zine/ketamine. The cranium of each anesthetized mouse
was fixed in a stereotactic frame fitted with a small animal
adaptor. A 1.5 mm burr hole was made in the cranium
exactly 2.5 mm lateral to bregma. A 26 g beveled tip Ham-
ilton syringe was used to inject 10 μl of tumor cell solu-
tion into the posterior striatum of the mouse. Animals
demonstrating symptoms of disease were euthanized by
barbiturate overdose followed by decapitation, 28–34
days post-inoculation. Brains were surgically removed
and snap frozen. For RNA isolation, tumors were dis-
sected free from non-neoplastic brain. For immunohisto-
chemistry, whole brains were sectioned.
Cerebral ischemia
Focal cerebral ischemia was produced by intraluminal
occlusion of the left middle cerebral artery (MCAO) with
a nylon monofilament suture as previously described [21-
23]. In brief, male 2- to 3-month-old C57/B6 mice (The
Jackson Laboratory, Bar Harbor, ME) were anesthetized
with 1.5% isoflurane in a 30%02/68.5% N2O mixture
under spontaneous breathing. Systolic arterial blood pres-
sure was monitored through a tail cuff (XBP1000 Systems,
Kent Scientific Corporation, Torrington, CA) and arterial
blood gas was analyzed at 15 min before and 30 min after
the onset of ischemia. The animals underwent MCAO for
90 minutes. Changes in regional blood flow were evalu-
ated before, during and after MCAO using laser Doppler
flowmetry. Brains were harvested at the indicated times
after surgery and snap frozen.
Antibodies
Anti-PV-1 (meca-32) rat polyclonal antibody and anti-
CD31 rat polyclonal antibody were from BD Biosciences
Pharmingen (San Jose, CA). Biotinylated rabbit-anti-rat
secondary antibody was from Vector Laboratories (Burlin-
game, CA).
Immunohistochemistry
Brains were frozen in OCT and sliced through the tumor
into 10 μm coronal sections. Sections were fixed in -20°C
acetone for 15 minutes. Slides were washed in 1× PBS and
then quenched with 0.3% H202 in 0.3% normal serum/1×
PBS for 5 minutes. Slides were washed in 1× PBS then
blocked for 30 minutes with 4% normal rabbit serum/
1xPBS. Sections were exposed to anti-PV-1 (1:100) or anti-
CD31 (1:500) at 4°C overnight. Sections were washed
with 1× PBS and exposed for 1 hr to biotinylated rabbit-
anti-rat secondary, diluted 1:1000 for PV-1 and 1:2500 for
CD31. Sections were washed in 1× PBS then exposed to
Vectastain ABC (Vector) for 30 minutes. Sections were
washed in 1× PBS and incubated with NovaRed substrate
(Vector) for 15 minutes. Slides were rinsed with distilled
water and counterstained with Mayer's Hematoxylin
(Biomeda, Foster City, CA). Sections were rinsed with dis-
tilled water, exposed to 0.08% NH4OH for 3 minutes,
then rinsed again with distilled water. Crystal Mount
(Biomeda) was applied to slides and allowed to dry over-
night.
Vessel Quantitation
Ischemic and control brain sections were immunostained
for PV-1 or CD31, as described above. Two lesioned or
control animals were counted for each protein at 8 h, 24
h, 48 h and 7d post-infarct (four animals per time point),
with the exception of 8 h, where one unique animal was
analyzed for each stain. The number of vessels in five non-
overlapping, representative fields within the ischemic
(both core and penumbra) or corresponding control zone
was counted at 400× magnification on each slide. Statisti-
cal significance was determined by two-way ANOVA anal-
ysis.
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